Dandruff, Seborrheic Dermatitis, and Psoriasis Drug Products for Over-the-Counter Human Use; Amendment to the Monograph

摘要

The Food and Drug Administration (FDA) is issuing a final rule amending the final monograph for over-the-counter (OTC) dandruff, seborrheic dermatitis, and psoriasis drug products to include 0.6 percent micronized selenium sulfide for the control of dandruff. This final rule is part of the ongoing review of OTC drug products conducted by FDA.